SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-16-118017
Filing Date
2016-05-05
Accepted
2016-05-05 08:43:15
Documents
54
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q a16-6663_110q.htm 10-Q 723262
2 EX-31.1 a16-6663_1ex31d1.htm EX-31.1 11892
3 EX-31.2 a16-6663_1ex31d2.htm EX-31.2 12505
4 EX-32.1 a16-6663_1ex32d1.htm EX-32.1 8276
  Complete submission text file 0001104659-16-118017.txt   3964191

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cldx-20160331.xml EX-101.INS 973552
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cldx-20160331.xsd EX-101.SCH 31793
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cldx-20160331_cal.xml EX-101.CAL 51247
8 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT cldx-20160331_lab.xml EX-101.LAB 308637
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cldx-20160331_pre.xml EX-101.PRE 199672
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cldx-20160331_def.xml EX-101.DEF 88838
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 161621740
SIC: 2835 In Vitro & In Vivo Diagnostic Substances